Sign in
CompletedNo phase

AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients

Key facts

Who runs it
Changhai Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
504 people enrolled
Started
1 Mar 2023
Ended
1 Jan 2024
Type of study
Observational
Record updated
26 February 2024

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • gender and age are not restricted
  • diagnosis of chronic pancreatitis
  • fe-1 test was conducted following recent pancreatic enhanced CT
  • sign informed consent

Who cannot take part

  • previous pancreatic surgery
  • history of malignant tumor
  • systemic diseases
  • enhanced CT was taken during the acute episode of chronic pancreatitis
  • poor image quality or image loss

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Early assessment of pancreatic exocrine insufficiency (PEI) is crucial for determining appropriate chronic pancreatitis (CP) treatment plans, thereby avoiding unnecessary suffering and further complications in patients. A total of 504 patients with CP who underwent fecal elastase-1 test and contrast-enhanced CT at Changhai Hospital between January 2018 and April 2023 were enrolled in this study. The investigators aim to establish a fully automated workflow to establish a PEI classification model based on radiomic features, semantic features and deep learning features on enhanced CT images for evaluating the severity of PEI.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Artificial Intelligence Assistance of Pancreatic Exocrine Insufficiency Evaluation in Chronic Pancreatitis From Contrast-Enhanced CT
Record updated
26 February 2024